{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:29:19Z","timestamp":1793212159345,"version":"4.5.0"},"reference-count":68,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.cgh.2026.02.006","type":"journal-article","created":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:47:14Z","timestamp":1770943634000},"page":"2075-2093","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Effectiveness and Safety of Janus Kinase Inhibitors in Acute Severe Ulcerative Colitis: A Systematic Review and Meta-Analysis"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9074-6698","authenticated-orcid":false,"given":"Anuraag","family":"Jena","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhirup","family":"Chatterjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arup","family":"Choudhury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishal","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaji","family":"Sebastian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2026.02.006_bib1","doi-asserted-by":"crossref","first-page":"579","DOI":"10.4291\/wjgp.v5.i4.579","article-title":"Management of acute severe ulcerative colitis","volume":"5","author":"Kedia","year":"2014","journal-title":"World J Gastrointest Pathophysiol"},{"key":"10.1016\/j.cgh.2026.02.006_bib2","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/ajg.2016.7","article-title":"Systematic review and meta-analysis: infliximab or cyclosporine as rescue therapy in patients with severe ulcerative colitis refractory to steroids","volume":"111","author":"Narula","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2026.02.006_bib3","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.cgh.2006.09.033","article-title":"Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression","volume":"5","author":"Turner","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2026.02.006_bib4","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/s12664-024-01522-4","article-title":"Modern practical management of acute severe colitis","volume":"43","author":"AbdelMeguid","year":"2024","journal-title":"Indian J Gastroenterol"},{"key":"10.1016\/j.cgh.2026.02.006_bib5","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1111\/apt.13913","article-title":"Review article: dose optimisation of infliximab for acute severe ulcerative colitis","volume":"45","author":"Hindryckx","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2026.02.006_bib6","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1136\/flgastro-2019-101277","article-title":"Practice pattern variability in the management of acute severe colitis: a UK provider survey","volume":"11","author":"Sebastian","year":"2019","journal-title":"Frontline Gastroenterol"},{"key":"10.1016\/j.cgh.2026.02.006_bib7","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S2468-1253(16)30003-6","article-title":"Infliximab versus ciclosporin for steroid-resistant acute severe ulcerative colitis (CONSTRUCT): a mixed methods, open-label, pragmatic randomised trial","volume":"1","author":"Williams","year":"2016","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2026.02.006_bib8","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.dld.2008.03.014","article-title":"Colectomy rate in acute severe ulcerative colitis in the infliximab era","volume":"40","author":"Aratari","year":"2008","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.cgh.2026.02.006_bib9","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1016\/j.cgh.2022.11.029","article-title":"Upadacitinib therapy reduces ulcerative colitis symptoms as early as day 1 of induction treatment","volume":"21","author":"Loftus","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2026.02.006_bib10","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1080\/17474124.2022.2106216","article-title":"Positioning of tofacitinib in treatment of ulcerative colitis: a global perspective","volume":"16","author":"Mishra","year":"2022","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2026.02.006_bib11","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1007\/s40262-017-0605-6","article-title":"Population pharmacokinetics of upadacitinib in healthy subjects and subjects with rheumatoid arthritis: analyses of phase I and II clinical trials","volume":"57","author":"Kl\u00fcnder","year":"2018","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.cgh.2026.02.006_bib12","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.cgh.2026.02.006_bib13","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1016\/j.cgh.2024.10.029","article-title":"Acute severe ulcerative colitis: an international Delphi consensus on clinical trial design and endpoints","volume":"23","author":"Honap","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2026.02.006_bib14","series-title":"R: a language and environment for statistical computing","year":"2021"},{"key":"10.1016\/j.cgh.2026.02.006_bib15","series-title":"JBI Manual for Evidence Synthesis","article-title":"Chapter 7: systematic reviews of etiology and risk","author":"Moola","year":"2020"},{"key":"10.1016\/j.cgh.2026.02.006_bib16","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1016\/j.cgh.2021.05.038","article-title":"Tofacitinib for biologic-experienced hospitalized patients with acute severe ulcerative colitis: a retrospective case-control study","volume":"19","author":"Berinstein","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2026.02.006_bib17","doi-asserted-by":"crossref","DOI":"10.14309\/ajg.0000000000002674","article-title":"Effectiveness of upadacitinib for patients with acute severe ulcerative colitis: a multicenter experience","author":"Berinstein","year":"2024","journal-title":"Am J Gastroenterol."},{"key":"10.1016\/j.cgh.2026.02.006_bib18","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s00384-025-04825-w","article-title":"Upadacitinib as rescue therapy for corticosteroid failure acute severe ulcerative colitis: an Asian experience from Taiwan","volume":"40","author":"Chung","year":"2025","journal-title":"Int J Colorectal Dis"},{"key":"10.1016\/j.cgh.2026.02.006_bib19","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1097\/MPG.0000000000003616","article-title":"Tofacitinib salvage therapy for children hospitalized for corticosteroid- and biologic-refractory ulcerative colitis","volume":"75","author":"Constant","year":"2022","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.cgh.2026.02.006_bib20","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1093\/jcag\/gwad042","article-title":"The role of tofacitinib in the treatment of acute severe colitis in children","volume":"7","author":"Costaguta","year":"2023","journal-title":"J Can Assoc Gastroenterol"},{"key":"10.1016\/j.cgh.2026.02.006_bib21","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1093\/ibd\/izae038","article-title":"Clinical outcomes at 8-16 weeks after upadacitinib initiation for acute severe ulcerative colitis: a case series in the United States","volume":"30","author":"Dalal","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2026.02.006_bib22","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1111\/imj.16192","article-title":"Outcomes out to 12 months after sequential use of high-dose tofacitinib following infliximab in acute severe ulcerative colitis","volume":"53","author":"Eqbal","year":"2023","journal-title":"Intern Med J"},{"key":"10.1016\/j.cgh.2026.02.006_bib23","doi-asserted-by":"crossref","DOI":"10.1177\/17562848251323511","article-title":"Sequential rescue therapy with JAK inhibitors in corticosteroid and infliximab-refractory acute severe ulcerative colitis: a case series","volume":"18","author":"Etchegaray","year":"2025","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1016\/j.cgh.2026.02.006_bib24","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1111\/apt.17938","article-title":"Effectiveness and safety of a third-line rescue treatment for acute severe ulcerative colitis refractory to infliximab or ciclosporin (REASUC study)","volume":"59","author":"Garc\u00eda","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2026.02.006_bib25","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1093\/ecco-jcc\/jjab109","article-title":"Sequential use of high-dose tofacitinib after infliximab salvage therapy in acute severe ulcerative colitis","volume":"16","author":"Gilmore","year":"2022","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.cgh.2026.02.006_bib26","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1093\/ecco-jcc\/jjad115","article-title":"Upadacitinib salvage therapy for infliximab-experienced patients with acute severe ulcerative colitis","volume":"17","author":"Gilmore","year":"2023","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.cgh.2026.02.006_bib27","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.cgh.2025.07.025","article-title":"Comparative effectiveness of tofacitinib versus upadacitinib for the treatment of acute severe ulcerative colitis","volume":"24","author":"Honap","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2026.02.006_bib28","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1093\/ibd\/izae282.165","article-title":"Clinical outcomes of upadacitinib in adolescents with refractory acute severe colitis","volume":"31","author":"Khoo","year":"2025","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2026.02.006_bib29","first-page":"97","article-title":"Successful initial tofacitinib treatment for acute severe ulcerative colitis with steroid resistance: a case series","volume":"36","author":"Komeda","year":"2023","journal-title":"Ann Gastroenterol"},{"key":"10.1016\/j.cgh.2026.02.006_bib30","first-page":"74","article-title":"Upadacitinib for acute severe ulcerative colitis refractory to steroids and tumour necrosis factor-inhibitor therapy: a single-centre case series IBD clinical","volume":"40","author":"Lee","year":"2025","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2026.02.006_bib31","article-title":"Tofacitinib in steroid-refractory acute severe ulcerative colitis: a retrospective analysis","volume":"15","author":"Malakar","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.cgh.2026.02.006_bib32","doi-asserted-by":"crossref","first-page":"i1065","DOI":"10.1093\/ecco-jcc\/jjae190.0693","article-title":"P0519 Upadacitinib in acute severe ulcerative colitis among previously anti-TNFa exposed patients","volume":"19","author":"Manti","year":"2025","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.cgh.2026.02.006_bib33","first-page":"45","article-title":"Risk factors for colectomy in patients with a super-severe attack of ulcerative colitis","volume":"22","author":"Mingazov","year":"2023","journal-title":"Coloproctology"},{"key":"10.1016\/j.cgh.2026.02.006_bib34","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s12664-022-01336-2","article-title":"Low prevalence of Clostridioides difficile infection in acute severe ulcerative colitis: a retrospective cohort study from northern India","volume":"42","author":"Mundhra","year":"2023","journal-title":"Indian J Gastroenterol"},{"key":"10.1016\/j.cgh.2026.02.006_bib35","article-title":"Tofacitinib for hospitalized acute severe ulcerative colitis management (the TRIUMPH Study)","volume":"7","author":"Narula","year":"2025","journal-title":"Crohns Colitis 360"},{"key":"10.1016\/j.cgh.2026.02.006_bib36","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.gastrohep.2023.10.003","article-title":"Colombian experience with the use of tofacitinib in severe acute ulcerative colitis: a case series study","volume":"47","author":"Parra-Izquierdo","year":"2024","journal-title":"Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2026.02.006_bib37","first-page":"401","article-title":"Intensified upadacitinib dosing for adolescent patients with acute severe ulcerative colitis","volume":"12","author":"Patel","year":"2025","journal-title":"Children (Basel)"},{"key":"10.1016\/j.cgh.2026.02.006_bib38","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1093\/ibd\/izad135","article-title":"Real-life efficacy of tofacitinib in various situations in ulcerative colitis: a retrospective worldwide multicenter collaborative study","volume":"30","author":"Res\u00e1l","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2026.02.006_bib39","first-page":"A14.1","article-title":"OC18 A single-centre experience utilising tofacitinib in paediatric acute severe colitis: focus on colectomy-free survival and adverse events","volume":"15","author":"Rose","year":"2024","journal-title":"Frontline Gastroenterol"},{"key":"10.1016\/j.cgh.2026.02.006_bib40","doi-asserted-by":"crossref","DOI":"10.14309\/01.ajg.0001035076.31031.76","article-title":"S1427A single center experience of upadacitinib treatment for acute severe ulcerative colitis","volume":"119","author":"Schreiber-Stainthorp","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2026.02.006_bib41","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjae190.0767","article-title":"P0593 high-dose tofacitinib in acute severe ulcerative colitis: an option to avoid colectomy?","volume":"19","author":"Sierra Ausin","year":"2025","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.cgh.2026.02.006_bib42","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.14309\/ajg.0000000000002635","article-title":"Tofacitinib in acute severe ulcerative colitis (TACOS): a randomized controlled trial","volume":"119","author":"Singh","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2026.02.006_bib43","article-title":"Clinical spectrum of acute severe ulcerative colitis in the biologic era: a prospective cohort study from India","author":"Singh","year":"2025","journal-title":"Intest Res."},{"key":"10.1016\/j.cgh.2026.02.006_bib44","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjad212.1187","article-title":"P1057 upadacitinib as salvage therapy for acute severe ulcerative colitis: a single-center experience","volume":"18","author":"St-Pierre","year":"2024","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.cgh.2026.02.006_bib45","doi-asserted-by":"crossref","first-page":"i1877","DOI":"10.1093\/ecco-jcc\/jjae190.1189","article-title":"P1015 upadacitinib as a rescue therapy in patients with steroid- and infliximab-refractory acute severe ulcerative colitis: real-life multicentre results","volume":"19","author":"\u00dcnalG\u00fclsen","year":"2025","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.cgh.2026.02.006_bib46","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/apt.16463","article-title":"Tofacitinib as salvage therapy for 55 patients hospitalised with refractory severe ulcerative colitis: a GETAID cohort","volume":"54","author":"Uzzan","year":"2021","journal-title":"Aliment Pharmacolther"},{"key":"10.1016\/j.cgh.2026.02.006_bib47","doi-asserted-by":"crossref","first-page":"5213","DOI":"10.1007\/s10620-022-07439-2","article-title":"Effectiveness of tofacitinib for hospitalized patients with acute severe ulcerative colitis: case series","volume":"67","author":"Xiao","year":"2022","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.cgh.2026.02.006_bib48","doi-asserted-by":"crossref","first-page":"3320","DOI":"10.1093\/ibd\/izaf166","article-title":"Real-world experience with upadacitinib for pediatric acute severe ulcerative colitis: an international multicenter retrospective study from the Pediatric IBD Porto Group of ESPGHAN","volume":"31","author":"Yerushalmy-Feler","year":"2025","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2026.02.006_bib49","first-page":"1126","article-title":"Janus kinase inhibitors as a rescue therapy in acute severe ulcerative colitis: single-center retrospective study","volume":"13","author":"Zdychyncova","year":"2025","journal-title":"United European Gastroenterol J"},{"key":"10.1016\/j.cgh.2026.02.006_bib50","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s10238-024-01468-z","article-title":"Effectiveness and safety of upadacitinib in acute severe ulcerative colitis patients from single Chinese IBD center: a monocentric study","volume":"24","author":"Zhang","year":"2024","journal-title":"Clin Exp Med"},{"key":"10.1016\/j.cgh.2026.02.006_bib51","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.jclinepi.2014.03.003","article-title":"In meta-analyses of proportion studies, funnel plots were found to be an inaccurate method of assessing publication bias","volume":"67","author":"Hunter","year":"2014","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.cgh.2026.02.006_bib52","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000015987","article-title":"The trim-and-fill method for publication bias: practical guidelines and recommendations based on a large database of meta-analyses","volume":"98","author":"Shi","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.cgh.2026.02.006_bib53","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1136\/gutjnl-2021-326390","article-title":"Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis","volume":"71","author":"Burr","year":"2022","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2026.02.006_bib54","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjae111","article-title":"Rescue therapies for steroid-refractory acute severe ulcerative colitis: a systemic review and network meta-analysis","author":"Huang","year":"2024","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.cgh.2026.02.006_bib55","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/j.dld.2023.05.021","article-title":"The current role of tofacitinib in acute severe ulcerative colitis in adult patients: a systematic review","volume":"55","author":"Mpakogiannis","year":"2023","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.cgh.2026.02.006_bib56","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1093\/ibd\/izae191","article-title":"Upadacitinib for acute severe ulcerative colitis: a systematic review","volume":"31","author":"Damianos","year":"2025","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2026.02.006_bib57","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1093\/ibd\/izad279","article-title":"Use of upadacitinib in 16 tofacitinib-refractory ulcerative colitis patients: a single-center case series","volume":"30","author":"Levine","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2026.02.006_bib58","doi-asserted-by":"crossref","DOI":"10.14309\/crj.0000000000001673","article-title":"Upadacitinib monotherapy after tofacitinib failure was successful for induction but not maintenance of remission in medically refractory ulcerative colitis","volume":"12","author":"Chatto","year":"2025","journal-title":"ACG Case Rep J"},{"key":"10.1016\/j.cgh.2026.02.006_bib59","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjaf154","article-title":"Is 2nd JAKi treatment for UC worth the effort? A retrospective, multi-centre UK study","volume":"19","author":"Radia","year":"2025","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.cgh.2026.02.006_bib60","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjae190.1203","article-title":"P1029 Janus kinase inhibitors for the management of acute severe ulcerative colitis: a multicentre study","volume":"19","author":"Gilmore","year":"2025","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.cgh.2026.02.006_bib61","doi-asserted-by":"crossref","first-page":"7140","DOI":"10.1038\/s41598-022-10777-w","article-title":"Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database","volume":"12","author":"Hoisnard","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.cgh.2026.02.006_bib62","article-title":"Safety profile and dose-dependent adverse events of upadacitinib in randomized clinical trials: a systematic review and meta-analysis","volume":"16","author":"Zhang","year":"2025","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.cgh.2026.02.006_bib63","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1241954","article-title":"Risk of herpes zoster associated with JAK inhibitors in immune-mediated inflammatory diseases: a systematic review and network meta-analysis","volume":"14","author":"Xu","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.cgh.2026.02.006_bib64","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s00296-022-05270-6","article-title":"Herpes zoster in patients with inflammatory arthritides or ulcerative colitis treated with tofacitinib, baricitinib or upadacitinib: a systematic review of clinical trials and real-world studies","volume":"43","author":"Gialouri","year":"2023","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.cgh.2026.02.006_bib65","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1016\/j.cgh.2025.01.032","article-title":"Postoperative outcomes in tofacitinib-treated patients with acute severe ulcerative colitis undergoing colectomy","volume":"23","author":"Larson","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2026.02.006_bib66","doi-asserted-by":"crossref","first-page":"e57","DOI":"10.1097\/MPG.0000000000003190","article-title":"Tofacitinib therapy in children and young adults with pediatric-onset medically refractory inflammatory bowel disease","volume":"73","author":"Moore","year":"2021","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.cgh.2026.02.006_bib67","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1093\/ibd\/izae112","article-title":"Tofacitinib in pediatric ulcerative colitis: a retrospective multicenter experience","volume":"31","author":"Ledder","year":"2025","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2026.02.006_bib68","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/jpn3.12408","article-title":"Upadacitinib is associated with clinical response and steroid-free remission for children and adolescents with inflammatory bowel disease","volume":"80","author":"Runde","year":"2025","journal-title":"J Pediatr Gastroenterol Nutr"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356526001060?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356526001060?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T07:47:11Z","timestamp":1784706431000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542356526001060"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":68,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S1542356526001060"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2026.02.006","relation":{},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness and Safety of Janus Kinase Inhibitors in Acute Severe Ulcerative Colitis: A Systematic Review and Meta-Analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2026.02.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Gastroenterological Association Institute. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}